Skip to main content
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc — Investor Relations & Filings

Ticker · PTGX ISIN · US74366E1029 US Manufacturing
Open in API
Filings indexed 641 across all filing types
Latest filing 2017-09-21 Regulatory Filings
Country US United States of America
Listing US PTGX

About Protagonist Therapeutics, Inc

https://www.protagonist-inc.com/

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of peptide-based new chemical entities. The company utilizes its proprietary technology platform to engineer novel oral and injectable peptide therapeutics. Its development pipeline is focused on creating treatments for rare and prevalent diseases, particularly in the areas of hematology and gastroenterology, addressing significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings Classification · 90% confidence The provided document text appears to be an encoded or binary file content (e.g., base64 or uuencoded data) rather than readable text. There are no discernible keywords, regulatory headers, form names, fiscal period dates, or document titles that can be extracted from the text. The document length is 15,000 characters, which is substantial, but the content is not human-readable and does not contain any clear indicators of the filing type. Given the lack of identifiable information and the nature of the content, the best classification is Regulatory Filings (RNS), which serves as a fallback category for miscellaneous filings that do not fit into other specific categories.
2017-09-21 English
FORM 4 SUBMISSION
Director's Dealing
2017-09-13 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering under the Securities Act of 1933. It includes a base prospectus describing the terms of securities offerings (common stock, preferred stock, debt securities) and mentions the potential for supplements and sales agreements. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual registration statement and prospectus, not just an announcement or notice.
2017-09-01 English
Regulatory Filings 2017
Regulatory Filings
2017-09-01 English
FORM 4 SUBMISSION
Director's Dealing
2017-08-31 English
FORM 4 SUBMISSION
Director's Dealing
2017-08-30 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.